The HeartMate III LVAS has a centrifugal blood pump that is implanted directly onto a patient's native heart and takes over the pumping ability of the weakened heart's left ventricle, which is responsible for pumping oxygen-rich blood from the lungs throughout the body. The device is implanted above the diaphragm and is attached to the aorta (the main artery that feeds blood into the entire body), leaving natural circulation in place while providing energy to propel blood throughout the body. The patient wears an external, wearable controller and battery system that powers the pump.
A HeartMate III Left Ventricular Assist System (LVAS) U.S. Clinical Trial will compare the HeartMate III LVAS to the HeartMate II® LVAS in advanced stage heart failure patients. Barnes-Jewish Hospital is one of the centers involved in the trial. The study will evaluate the device for use as long-term support for patients who are not candidates for cardiac transplantation (also known as Destination Therapy). It will also be evaluated for patients awaiting transplantation (Bridge-to-Transplantation).